Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
$0.00
$0.00
$0.00
N/A1.561,100 shsN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
$0.00
+∞
$0.00
$0.00
$0.00
N/A1.9818 shs2,200 shs
AKSY
Aksys
$0.00
$0.00
$0.00
N/AN/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
$0.01
$0.01
$0.01
$0.07
N/A-0.1910,580 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
0.00%0.00%-75.00%-75.00%-83.33%
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00%0.00%0.00%0.00%0.00%
AKSY
Aksys
0.00%0.00%0.00%0.00%0.00%
Remedent, Inc. stock logo
REMI
Remedent
-0.22%-10.20%-10.20%-62.74%-83.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/AN/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
0.00
N/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00
N/AN/AN/A
AKSY
Aksys
0.00
N/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
$270KN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
$990KN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
-$510KN/A0.00N/AN/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/A0.00N/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
-$270K-$0.01N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/AN/AN/AN/AN/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/A
AKSY
Aksys
N/AN/AN/AN/AN/A
Remedent, Inc. stock logo
REMI
Remedent
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
N/A
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/A
AKSY
Aksys
N/A
Remedent, Inc. stock logo
REMI
Remedent
N/A

Insider Ownership

CompanyInsider Ownership
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
34.11%
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
17.40%
AKSY
Aksys
3.80%
Remedent, Inc. stock logo
REMI
Remedent
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Biomedical Technologies, Inc. stock logo
ABMT
Advanced Biomedical Technologies
20N/AN/ANot Optionable
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
6N/AN/ANot Optionable
AKSY
Aksys
87N/AN/ANot Optionable
Remedent, Inc. stock logo
REMI
Remedent
4N/AN/ANot Optionable

Recent News About These Companies

Reviewing Remedent (REMI) & Its Competitors
Financial Analysis: Remedent (REMI) vs. Its Peers
Rémi Laurent Biography & Movies
Rémi Laurent Biography & Movies
REMYY Rémy Cointreau SA
Remi Lambert
Peterson Remy
Remi Monaghan
remy ma and papoose
Rémi Bonnet Breaks Longtime Pikes Peak Ascent Record
Home and Away spoiler: Remi keeps quiet about the kiss

Top Headlines

View All Headlines
Advanced Biomedical Technologies stock logo

Advanced Biomedical Technologies OTCMKTS:ABMT

Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.

Alliqua BioMedical stock logo

Alliqua BioMedical OTCMKTS:ADYX

$0.0001 +0.00 (+∞)
As of 07/15/2025 05:20 PM Eastern

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Aksys OTCMKTS:AKSY

Aksys Ltd. provides hemodialysis products and services for patients suffering from end-stage renal disease, known as chronic kidney failure. The company offers an automated personal hemodialysis system, known as the Aksys PHD, a Personal Hemodialysis System (PHD System), which is designed to enable patients to perform frequent hemodialysis at alternate sites, such as their own homes. The PHD System is designed to monitor, during the treatment, various vital statistics, including the patient's blood flow rate, the amount of water removed from the patient, the length of the treatment session, and other parameters. It also evaluates the performance of the artificial kidney in removing toxins from the patient's blood prior to each treatment, as well as automatically evaluates the water treatment filters and indicates whether a replacement is required and verifies that safety systems, sensors, and alarms are operating correctly. Aksys Ltd. also provides various services, including the delivery and installation of the PHD System; technical services, including maintenance and repair of the PHD System; delivery of consumables used in dialysis, such as the water purification components and dialysate concentrate; and artificial kidney, and arterial and venous blood tubing. The company markets its products and services, primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups in the United States, the United Kingdom, and Japan. Aksys Ltd. was founded in 1991 and is headquartered in Lincolnshire, Illinois.

Remedent stock logo

Remedent OTCMKTS:REMI

$0.0090 0.00 (0.00%)
As of 07/17/2025

Remedent, Inc. researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products in the United States and internationally. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use. The company also offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. In addition, it provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth. Further, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice that enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner. Additionally, it provides dental implant solutions and treatment concepts. The company sells its products through internal sales force and third party distributors. Remedent, Inc. was incorporated in 1986 and is headquartered in Ghent, Belgium.